Art Krieg, Checkmate

Art Krieg’s Check­mate ex­e­cutes a snap­py 1-2 biotech gam­bit — big crossover fol­lowed by an in­stant IPO

Just as ex­pect­ed, Check­mate’s $85 mil­lion ven­ture raise a few weeks ago was a pre­quel to the lat­est biotech IPO to hit the queue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.